Open Beta
TREN
MetriLume
TREN

US marketsINM

SEC-sourced researchBeta

INM

InMed Pharmaceuticals Inc.

Company comparison ↗

Data passport

CIK
0001728328
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Oct 5, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: June 2024: 4,597,730.0000 USD; June 2025: 4,942,633.0000 USD4.9M USD0 USD0June 2024June 2025
INM · Exact amounts and source periods · USD
Period endRevenueFiling date
June 20244,597,730.0000Sep 23, 2025
June 20254,942,633.0000Sep 23, 2025

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
June 20254,942,633.0000-8,162,133.0000-7,766,951.000015,580,040.00002,145,545.0000Sep 23, 2025
June 20244,597,730.0000-7,675,550.0000-6,985,832.000011,822,782.00002,616,673.0000Sep 23, 2025

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$4.94MJune 2025Sep 23, 202510-K
Previous period revenueRevenues$4.6MJune 2024Sep 23, 202510-K
Net incomeNetIncomeLoss-$8.16MJune 2025Sep 23, 202510-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$7.77MJune 2025Sep 23, 202510-K
Total assetsAssets$15.58MJune 2025Sep 23, 202510-K
Total liabilitiesLiabilities$2.15MJune 2025Sep 23, 202510-K

New filings

Explore methodology ↗